Name: India MCA Corporate Compliance Enforcement — May 26, 2026
Creator: Gunpowder
Published: 2026-05-26T15:31:57.494Z
License: https://www.gunpowderalerts.in/terms

21 high priority 21 total filings analysed

Executive Summary

The 21 filings in this MCA Compliance & Enforcement stream reveal a mixed picture for Indian corporates, with significant divergence between top-line growth and profitability.

While Godavari Biorefineries and Fine Organic Industries reported modest FY26 revenue growth (6% and 4.3% YoY respectively), Camlin Fine Sciences saw a dramatic profit swing to a consolidated net loss of ₹3,710.29 Lakh from a profit of ₹2,354.32 Lakh in FY25, driven by margin compression and exceptional items. A key theme is the prevalence of procedural and compliance-related filings (13 of 21), including secretarial compliance reports, penalty waivers, and investor meeting disclosures, which signal heightened regulatory scrutiny but low materiality. Notably, Patel Engineering received a ₹14 Lakh penalty for operating without a license, while Aurum PropTech successfully waived a ₹53,100 fine, indicating that enforcement actions are occurring but are often minor. The most critical development is the sharp deterioration in Camlin Fine Sciences' profitability, with EBITDA margin contracting from 13.3% to 6.2% and a net loss of ₹315.3 mn from continuing operations, contrasting with Fine Organic's stable 20.4% EBITDA margin. Portfolio-level patterns show a focus on capacity expansion (Godavari's new distillery, Gandhar's land purchase) and international forays (Fine Organic's Malaysia acquisition, Gandhar's South Africa subsidiary), suggesting a strategic pivot towards growth despite near-term headwinds.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Tracking the trend? Catch up on the prior India MCA Corporate Compliance Enforcement digest from May 25, 2026.

Investment Signals (10)

Godavari Biorefineries ↓
▲

FY26 total income up 6.0% YoY to ₹2,000.2 Cr, EBITDA up 15.8% YoY to ₹139.3 Cr (margin 7.0%), and finance costs down 31.6% YoY after ₹240 Cr debt repayment. However, Q4 revenue declined 2.7% YoY and EBITDA fell 24.3% YoY, signaling a mixed trend. [BULLISH/BEARISH]
Camlin Fine Sciences ↓ (BEARISH)
▲

Consolidated revenue grew 5.8% YoY to ₹172,330.81 Lakh, but net profit swung to a loss of ₹3,710.29 Lakh from a profit of ₹2,354.32 Lakh in FY25. EBITDA margin halved from 13.3% to 6.2%, and Q4 EBITDA margin contracted sharply to 5.0% from 14.4% YoY.
Fine Organic Industries ↓ (BULLISH)
▲

FY26 revenue grew 4.3% YoY to INR 2,365 crore, PAT up 1.6% YoY to INR 417 crore, with a stable EBITDA margin of 20.4%. The company announced an 80% stake acquisition in Oleofine Organics BHD (Malaysia) for ~INR 82.9 crore, expected to close within 3 months.
Camlin Fine Sciences - Segment Weakness ↓ (BEARISH)
▲

Straights revenue declined 17% QoQ in Q4 FY26 due to lower Methyl Vanillin production and channel stock liquidation. Performance Chemicals segment fell 46% QoQ and 23% YoY, indicating broad-based demand weakness.
Godavari Biorefineries - Capacity Expansion ↓ (BULLISH)
▲

Commissioning a new 200 KLPD grain-based distillery by June 2026, which could drive future revenue growth and improve product mix.
Fine Organic Industries - Capacity Utilization ↓ (BULLISH)
▲

All manufacturing facilities operated at near full capacity during FY26, and the Patalganga food additives facility is expected to reach full capacity in the next financial year, indicating strong demand.
Aurum PropTech ↓ (BULLISH)
▲

Successfully waived a ₹53,100 fine from BSE for non-compliance with Regulation 23(9), demonstrating proactive regulatory engagement.
DCM Shriram Fine Chemicals ↓ (BULLISH)
▲

Annual Secretarial Compliance Report confirmed full compliance with all SEBI regulations with no instances of non-compliance, fines, or penalties since listing on February 17, 2026.
Gandhar Oil Refinery ↓ (BULLISH)
▲

Board approved incorporation of a wholly-owned subsidiary in South Africa and purchase of ~21,551 sq. mtrs land in Raigad, signaling expansion plans. Unmodified audit opinion received.
Godavari Biorefineries - Secretarial Compliance ↓ (BULLISH)
▲

Annual Secretarial Compliance Report confirmed no actions taken by SEBI or stock exchanges against the company, its promoters, or directors during FY26.

Risk Flags (8)

Camlin Fine Sciences - Profitability Collapse↓ [HIGH RISK]
▼

Consolidated net profit swung from a profit of ₹2,354.32 Lakh in FY25 to a loss of ₹3,710.29 Lakh in FY26, a deterioration of ₹6,064.61 Lakh. Standalone revenue declined 5.5% YoY to ₹83,791.82 Lakh.
Camlin Fine Sciences - Margin Compression↓ [HIGH RISK]
▼

EBITDA margin contracted from 13.3% in FY25 to 6.2% in FY26, a decline of 710 bps. Q4 FY26 EBITDA margin was just 5.0%, down from 14.4% in Q4 FY25.
Patel Engineering - Regulatory Penalty↓ [MEDIUM RISK]
▼

Penalty of ₹14 Lacs imposed by Forest and Environment department for operating a stone crusher plant without a mandatory operational license for three fiscal years (FY22-23, FY23-24, FY25-26).
Camlin Fine Sciences - Segment Decline↓ [HIGH RISK]
▼

Performance Chemicals segment declined 46% QoQ and 23% YoY in Q4 FY26. Straights revenue fell 17% QoQ. Aroma Ingredients revenue declined 12% QoQ.
Fine Organic Industries - Cost Headwinds↓ [MEDIUM RISK]
▼

Elevated raw material costs, freight disruptions from the West Asia conflict, and uneven global demand. Management expects raw material prices to remain high in the near term.
Godavari Biorefineries - Q4 Weakness↓ [MEDIUM RISK]
▼

Q4 FY26 revenue declined 2.7% YoY to ₹564.1 Cr, EBITDA fell 24.3% YoY to ₹92.1 Cr, and PAT (excl. one-time deferred tax) declined 26.5% YoY to ₹52.9 Cr. The integrated sugar, co-gen & ethanol segment saw a 5.6% YoY revenue decline in Q4.
Camlin Fine Sciences - CFO Change↓ [LOW RISK]
▼

The board approved appointment of Mr. Pankaj Pandey as CFO effective August 18, 2026, and re-designated Mr. Santosh Parab as President – Strategy and Global CFO. Leadership transitions can create operational uncertainty.
Patel Engineering - Operational License Gap↓ [MEDIUM RISK]
▼

Company claims it was unaware of the mandatory operational license requirement despite having 'Consent to Operate', indicating potential compliance gaps in project execution.

Opportunities (9)

Godavari Biorefineries - Debt Reduction↓ (OPPORTUNITY)
◆

Finance costs reduced 31.6% YoY to ₹49.1 Cr following ₹240 Cr debt repayment, improving net income and balance sheet strength. FY26 gross profit margin improved to 28.7% from 26.6% in FY25.
Fine Organic Industries - International Expansion↓ (OPPORTUNITY)
◆

Acquisition of 80% stake in Oleofine Organics BHD (Malaysia) for ~INR 82.9 crore, expected to close within 3 months. This provides a strategic foothold in Southeast Asia and diversifies revenue.
Fine Organic Industries - US Manufacturing↓ (OPPORTUNITY)
◆

New US manufacturing subsidiary in South Carolina announced, which could help mitigate tariff risks and serve North American customers more efficiently.
Gandhar Oil Refinery - Expansion in Raigad↓ (OPPORTUNITY)
◆

Purchase of ~21,551 sq. mtrs land in Raigad district suggests capacity expansion, which could drive future revenue growth.
Gandhar Oil Refinery - South Africa Subsidiary↓ (OPPORTUNITY)
◆

Proposed incorporation of a wholly-owned subsidiary in South Africa indicates international expansion strategy, potentially opening new markets.
Godavari Biorefineries - New Distillery↓ (OPPORTUNITY)
◆

Commissioning of 200 KLPD grain-based distillery by June 2026 is a near-term catalyst that could boost ethanol production capacity and revenue.
Fine Organic Industries - Capacity Ramp-up↓ (OPPORTUNITY)
◆

Patalganga food additives facility expected to reach full capacity in the next financial year, which could drive margin improvement and revenue growth.
Camlin Fine Sciences - Blends Business Growth↓ (OPPORTUNITY)
◆

Blends business saw steady annual growth of +17%, indicating a resilient segment that could offset weakness in Straights and Performance Chemicals.
DCM Shriram Fine Chemicals - Clean Compliance↓ (OPPORTUNITY)
◆

Newly listed company (Feb 17, 2026) with a clean compliance record, reducing regulatory risk for investors.

Sector Themes (5)

Revenue Growth vs. Profitability Divergence
◆

Across the filings, top-line growth (Godavari +6%, Camlin +5.8%, Fine Organic +4.3%) is not translating into bottom-line improvement. Camlin Fine Sciences saw a massive profit swing to loss, while Fine Organic managed only 1.6% PAT growth. This suggests rising input costs and competitive pressures are squeezing margins. Implication: Investors should favor companies with pricing power and cost control.
Capacity Expansion and International Forays
◆

Multiple companies are investing in capacity expansion (Godavari's distillery, Gandhar's land purchase, Fine Organic's Malaysia and US subsidiaries) and international subsidiaries (Gandhar in South Africa, Fine Organic in Dubai). Implication: This signals management confidence in long-term demand but also carries execution risk and capital outflows.
Regulatory Compliance as a Key Focus
◆

13 of 21 filings are procedural compliance disclosures (secretarial reports, investor meeting notices, penalty waivers). The high volume suggests companies are increasingly focused on meeting SEBI and MCA requirements. Implication: Companies with clean compliance records (DCM Shriram, Godavari) may be viewed more favorably by institutional investors.
Mixed Audit Opinions and Clean Reports
◆

All companies with financial results (Godavari, Camlin, Gandhar) received unmodified (clean) audit opinions, indicating no major accounting irregularities. However, Camlin's clean opinion contrasts sharply with its poor financial performance. Implication: Clean audits do not guarantee financial health; investors must look beyond audit opinions.
Management Stability vs. Change
◆

Gandhar Oil re-appointed joint managing directors for 5 years, signaling stability. Camlin Fine Sciences appointed a new CFO, indicating a potential strategic shift. Implication: Management continuity can be a positive signal, while CFO changes may warrant closer monitoring.

Watch List (8)

Camlin Fine Sciences - Q1 FY27 Results↓
👁

Watch for any improvement in EBITDA margins and segment performance, especially Straights and Performance Chemicals. Earnings call audio available at company website. Next quarterly results expected around August 2026.
Fine Organic Industries - Oleofine Acquisition Close↓
👁

The 80% stake acquisition in Oleofine Organics BHD (Malaysia) is expected to close within 3 months (by August 2026). Monitor for regulatory approvals and integration updates.
Godavari Biorefineries - New Distillery Commissioning↓
👁

The 200 KLPD grain-based distillery is expected to be commissioned by June 2026. Monitor for any delays and initial production ramp-up.
Patel Engineering - Teesta Stage-VI Project↓
👁

The company is executing a ₹1,251 Crore contract for NHPC's Teesta Stage-VI Hydro Electric Project. Watch for any further regulatory issues or project delays.
Fine Organic Industries - Investor Conference↓
👁

Company officials will attend Axis Capital Investor Conference on June 2, 2026. Watch for any new guidance or strategic updates shared during the meeting.
Camlin Fine Sciences - 33rd AGM↓
👁

Scheduled for August 11, 2026. Watch for shareholder resolutions, management commentary on turnaround plans, and any dividend announcements.
Gandhar Oil Refinery - South Africa Subsidiary↓
👁

Proposed incorporation of a wholly-owned subsidiary in South Africa. Monitor for regulatory approvals and initial capital allocation.
Godavari Biorefineries - Postal Ballot Outcome↓
👁

The company published a notice regarding a residential flat purchase. Watch for any claims or objections within the 15-day period ending June 10, 2026.

Filing Analyses (21)

Godavari Biorefineries Limited Regulatory Action mixed materiality 8/10

26-05-2026

Godavari Biorefineries Limited reported FY26 total income of ₹2,000.2 Cr, up 6.0% YoY, with EBITDA of ₹139.3 Cr (margin 7.0%) reflecting a 15.8% YoY increase. However, Q4 FY26 revenue declined 2.7% YoY to ₹564.1 Cr and EBITDA fell 24.3% YoY to ₹92.1 Cr, while the integrated sugar, co-gen & ethanol segment saw a 5.6% YoY revenue decline in Q4. The company reduced finance costs by 31.6% YoY to ₹49.1 Cr following ₹240 Cr debt repayment, and is commissioning a new 200 KLPD grain-based distillery by June 2026.

· Q4 FY26 gross profit margin was 39.2%, down from 39.3% in Q4 FY25.
· FY26 gross profit margin improved to 28.7% from 26.6% in FY25.
· Q4 FY26 profit after tax (excl. one-time deferred tax) was ₹52.9 Cr, down 26.5% YoY from ₹71.9 Cr.
· FY26 profit after tax (incl. one-time deferred tax) was ₹3.5 Cr vs a loss of ₹23.4 Cr in FY25.
· Q4 FY26 exceptional expenses were ₹3.4 Cr (gain), while FY26 exceptional expenses were ₹31.1 Cr (charge).
· Bio-based chemicals EBITDA margin in Q4 FY26 was 6.5%, down from 9.7% in Q4 FY25.
· Bio-based chemicals EBITDA margin for FY26 was 7.0%, down from 8.3% in FY25.
· The company sold 98 million litres of ethanol equivalent in FY26, with 81% under EBP, 13% ENA, and 6% others.
· New 200 KLPD grain-based distillery commissioning by June 2026 adds 60 million litres annual capacity.
· Jivana brand grew 19% YoY to ₹129 Cr revenue with 7,500+ store reach.
· US subsidiary Sathgen Therapeutics is advancing an oral TNBC inhibitor with CDSCO filing targeted for Q2 FY26.
· Japanese patent secured for novel antiviral therapy platform.

Godavari Biorefineries Limited Regulatory Action neutral materiality 1/10

26-05-2026

Godavari Biorefineries Limited has informed the stock exchanges that the audio recording of its earnings conference call for Q4 and FY26 has been uploaded on the company's website, as required under SEBI Listing Regulations. The filing is a procedural disclosure and contains no financial results or performance data.

· The audio recording link is: https://www.godavaribiorefineries.com/sites/default/files/Audio_Recording_Q4_and_FY_26.mp3
· Filing made under Regulation 46 of SEBI (LODR) Regulations, 2015
· Stock symbol: GODAVARIB (NSE), Script Code: 544279 (BSE)

Aurum PropTech Limited Regulatory Action positive materiality 3/10

26-05-2026

Aurum PropTech Limited received a waiver from BSE for a fine of ₹53,100 (inclusive of GST) that was originally imposed for non-compliance with Regulation 23(9) of the SEBI Listing Regulations. The fine was levied on December 16, 2025, and the company filed a waiver application on December 23, 2025, which was approved on May 25, 2026.

· The fine was originally imposed on December 16, 2025, for non-compliance with Regulation 23(9) of the SEBI Listing Regulations.
· The waiver application was filed on December 23, 2025.
· The waiver was approved via email from BSE on May 25, 2026.

DCM Shriram Fine Chemicals Ltd Regulatory Action positive materiality 3/10

26-05-2026

DCM Shriram Fine Chemicals Ltd has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as required under Regulation 24A of SEBI LODR Regulations. The report, issued by Chandrasekaran Associates (Company Secretaries), covers the review period from February 17, 2026 (listing date) to March 31, 2026, and states that the company has complied with all applicable SEBI regulations and circulars, with no instances of non-compliance, fines, penalties, or show-cause notices during the review period. The company's listing on stock exchanges occurred on February 17, 2026, and all policies under SEBI regulations have been adopted and are in conformity with requirements.

· Secretarial Compliance Report was issued by Chandrasekaran Associates, Company Secretaries (FRN: P1988DEO02500, Peer Review Certificate No: 6689/2025)
· The company was listed on stock exchanges on February 17, 2026 — the review period covers only 43 days from listing date to March 31, 2026
· All applicable policies under SEBI Regulations have been adopted and are in conformity with regulations
· The company maintains a functional website with timely dissemination of documents/information
· None of the directors are disqualified under Section 164 of the Companies Act, 2013
· Performance evaluation of the Board, Independent Directors and Committees was noted as not applicable since the company was listed only from February 17, 2026
· A scheme of arrangement was approved by the Hon'ble NCLT, Bench II, Delhi by Order dated 21.11.2025, pursuant to which all existing corporate approvals in relation to related party transactions will continue
· No actions taken by SEBI or Stock Exchanges against the company, its promoters, directors, or subsidiaries
· The company has complied with Regulation 3(5) & 3(6) of SEBI (Prohibition of Insider Trading) Regulations, 2015

Camlin Fine Sciences Limited Regulatory Action mixed materiality 8/10

26-05-2026

Camlin Fine Sciences Limited reported a mixed set of audited financial results for Q4 and FY ended March 31, 2026. On a consolidated basis, revenue from operations grew 5.8% YoY to ₹172,330.81 Lakh for FY26, but the company posted a net loss of ₹3,710.29 Lakh for the year, compared to a profit of ₹2,354.32 Lakh in FY25. The standalone performance also deteriorated, with a net loss of ₹564.95 Lakh in Q4 FY26 versus a profit of ₹1,561.84 Lakh in Q4 FY25. The board approved the appointment of Mr. Pankaj Pandey as CFO effective August 18, 2026, and re-designated Mr. Santosh Parab as President – Strategy and Global CFO.

· Consolidated revenue from operations for Q4 FY26 was ₹42,481.12 Lakh, down 3.6% from ₹44,051.07 Lakh in Q3 FY26.
· Standalone revenue from operations for FY26 was ₹83,791.82 Lakh, down 5.5% from ₹88,649.13 Lakh in FY25.
· Consolidated net loss for FY26 was ₹3,710.29 Lakh, compared to a net profit of ₹2,354.32 Lakh in FY25.
· Standalone net loss for Q4 FY26 was ₹564.95 Lakh, compared to a net profit of ₹1,561.84 Lakh in Q4 FY25.
· The company reported exceptional items of ₹2,546.01 Lakh on a consolidated basis for FY26.
· The 33rd Annual General Meeting is scheduled for August 11, 2026.
· The auditor's report has an unmodified opinion for both standalone and consolidated financial statements.
· Mr. Pankaj Pandey will join as CFO effective August 18, 2026; Mr. Santosh Parab will be re-designated as President – Strategy and Global CFO.

Camlin Fine Sciences Limited Regulatory Action mixed materiality 9/10

26-05-2026

Camlin Fine Sciences Limited (CFSL) reported Q4 FY26 revenue of ₹4,248 mn, slightly down from ₹4,315.8 mn in Q4 FY25, with EBITDA margin contracting sharply from 14.4% to 5.0%. Full-year FY26 revenue grew 5.8% to ₹17,233 mn from ₹16,287 mn, but EBITDA fell 51% to ₹1,069 mn (6.2% margin vs 13.3% in FY25), and PAT from continuing operations turned to a loss of ₹315.3 mn vs a profit of ₹650.9 mn in FY25. The Blends business saw steady growth (annual +17%), but Straights declined, and the company faced headwinds from raw material costs, currency fluctuations, and higher finance costs.

· Straights revenue declined 17% QoQ in Q4 FY26 (from ₹3,744 mn in Q3 FY26 to ₹3,114 mn) due to lower production of Methyl Vanillin and liquidation of internal channel stock.
· Performance Chemicals segment declined 46% in Q4 FY26 QoQ to ₹327 mn from ₹607 mn in Q3 FY26 and 23% YoY from ₹410 mn in Q4 FY25.
· Aroma Ingredients revenue declined 12% in Q4 FY26 QoQ to ₹702 mn from ₹765 mn in Q3 FY26, but grew 6% YoY from ₹961 mn in Q4 FY25.
· CFS India revenue declined 5% in FY26 vs FY25 (₹8,379 mn vs ₹8,865 mn).
· CFS North America revenue declined 6% in FY26 vs FY25 (₹3,362 mn vs ₹3,596 mn).
· CFS Mexico revenue grew 1% in FY26 to ₹5,090 mn from ₹5,062 mn in FY25.
· CFS Brazil revenue grew 3% in FY26 to ₹1,613 mn from ₹1,571 mn in FY25.
· CFS Vitafor revenue grew 53% in FY26 to ₹849 mn from ₹709 mn in FY25.
· CFS Vinpai contributed ₹165 mn revenue in Q4 FY26 (acquired 30th Nov 2026).
· Exceptional items in FY26 total ₹254.6 mn (continuing ops) vs ₹98.2 mn in FY25.
· Finance cost in FY26 rose to ₹729.4 mn from ₹963.0 mn in FY25 (decline of 24.3% due to lower borrowing rates).
· Current total borrowings (non-current + current) as at Mar-26 stood at ₹6,680.9 mn vs ₹6,161.4 mn as at Mar-25.
· Outlook for FY27: Vanillin realisations expected to improve with withdrawal of US tariff; Blends to achieve higher growth; oversupply from China may create opportunities; lingering conflict may hamper H1 FY27 growth.

Camlin Fine Sciences Limited Regulatory Action mixed materiality 8/10

26-05-2026

Camlin Fine Sciences Limited reported a mixed set of audited financial results for the quarter and year ended March 31, 2026. On a consolidated basis, revenue from operations grew 5.8% YoY to ₹172,330.81 Lakh, but the company reported a net loss of ₹3,710.29 Lakh for the year, a significant decline from a profit of ₹2,354.32 Lakh in FY25. The standalone business also showed weakness, with revenue declining 5.5% YoY and a net loss of ₹1,299.66 Lakh for the year. The Board also approved key management changes, including the appointment of Mr. Pankaj Pandey as CFO and the re-designation of Mr. Santosh Parab as President – Strategy and Global CFO.

· The statutory auditors, Kalyaniwalla & Mistry LLP, issued an unmodified (clean) opinion on the audited financial statements for FY26.
· The 33rd Annual General Meeting (AGM) is scheduled for August 11, 2026, via permissible mode.
· The Board appointed M/s. ABK & Associates as Cost Auditors and M/s. Mahajan & Aibara as Internal Auditors for FY27.
· Mr. Pankaj Pandey will join as CFO effective August 18, 2026, and Mr. Santosh Parab will be re-designated as President – Strategy and Global CFO on the same date.
· Consolidated total equity increased to ₹100,080.66 Lakh as of March 31, 2026, from ₹87,477.93 Lakh a year ago.
· Consolidated total borrowings (non-current + current) increased to ₹66,808.09 Lakh as of March 31, 2026, from ₹61,614.58 Lakh a year ago.
· Standalone net loss for the year improved significantly to ₹1,299.66 Lakh from a loss of ₹7,631.05 Lakh in FY25, driven by lower exceptional items and expenses.
· Consolidated basic EPS from continuing operations was ₹3.79 for FY26, compared to a loss of ₹1.59 in FY25.

Camlin Fine Sciences Limited Regulatory Action mixed materiality 8/10

26-05-2026

Camlin Fine Sciences reported a mixed set of audited financial results for Q4 and FY ended March 31, 2026. On a consolidated basis, revenue from operations grew 5.8% YoY to ₹172,330.81 Lakh, but the company posted a net loss of ₹3,710.29 Lakh for the year, compared to a profit of ₹2,354.32 Lakh in FY25, driven by exceptional items and higher expenses. Standalone performance was weaker, with revenue declining 5.5% YoY to ₹83,791.82 Lakh and a net loss of ₹1,299.66 Lakh for the year. The board also approved key management changes, including the appointment of Mr. Pankaj Pandey as CFO effective August 18, 2026.

· The board declared an unmodified opinion from statutory auditors Kalyaniwalla & Mistry LLP for FY26.
· The 33rd Annual General Meeting is scheduled for August 11, 2026 via permissible mode.
· Appointment of M/s. ABK & Associates as Cost Auditors and M/s. Mahajan & Aibara as Internal Auditors for FY27.
· Consolidated exceptional items for FY26 were ₹2,546.01 Lakh (FY25: ₹981.52 Lakh).
· Standalone exceptional items for FY26 were ₹1,626.95 Lakh (FY25: ₹9,600.21 Lakh).
· Consolidated basic EPS from continuing operations was ₹1.46 for FY26 vs ₹3.79 for FY25 (decline of 61.5%).
· Standalone basic EPS from continuing operations was a loss of ₹1.59 for FY26 vs a profit of ₹3.79 for FY25.
· Consolidated total equity increased to ₹100,080.66 Lakh as of March 31, 2026 from ₹87,477.93 Lakh a year ago.
· Standalone total equity increased to ₹92,882.54 Lakh from ₹86,226.92 Lakh.
· Consolidated total borrowings (non-current + current) stood at ₹66,808.09 Lakh as of March 31, 2026 vs ₹61,614.58 Lakh a year ago.
· Standalone total borrowings stood at ₹47,178.07 Lakh vs ₹41,231.69 Lakh a year ago.

Patel Engineering Limited Regulatory Action negative materiality 4/10

26-05-2026

Patel Engineering Limited disclosed a penalty of ₹14 Lacs imposed by the Forest and Environment department, Namthang, South Sikkim for operating a 200 THP Stone Crusher Plant at Thalthaley Pamphok, Sikkim without obtaining a mandatory operational license. The penalty covers FY 2022-23, 2023-24 and 2025-26. The company states it was unaware of the requirement and will pay the penalty and license fees, while noting no material financial impact and ongoing operations.

· Penalty received on May 25, 2026, disclosed on May 26, 2026.
· Company was executing a contract worth INR 1,251 Crore awarded by NHPC for the Teesta Stage-VI Hydro Electric Project.
· The company had obtained 'Consent to Operate' from the department but claims no mention was made of a mandatory operational license.
· Penalty is Rs. 14 lacs (flat) covering the years 2022-23, 2023-24 and 2025-26.

Fine Organic Industries Limited Regulatory Action neutral materiality 2/10

26-05-2026

Fine Organic Industries Ltd. informed stock exchanges that company officials will attend an investor conference organized by Axis Capital on June 2, 2026, via in-person one-on-one/group meetings. The investor presentation 'May 2026' has been uploaded to the company's website and stock exchange portals, with discussions limited to publicly available information and no UPSI intended to be shared.

· Meeting scheduled June 2, 2026, from 11:00 am to 04:00 pm
· Mode of meeting: in-person, One on One / Group
· Organizer: Axis Capital Investor Conference
· Investor presentation titled 'May 2026' is available on company website and stock exchanges
· Company confirms no UPSI will be discussed during interactions
· Filing submitted under Regulation 30(6) of SEBI LODR Regulations

Camlin Fine Sciences Limited Regulatory Action neutral materiality 1/10

26-05-2026

Camlin Fine Sciences Limited has informed the stock exchanges about the availability of the audio recording of the conference call held on May 26, 2026, regarding the audited financial results for the quarter and year ended March 31, 2026. The call was attended by senior management including the Chairman & Managing Director, Managing Director, and CFO. No unpublished price sensitive information was discussed.

· The conference call audio recording is available at https://www.camlinfs.com/investor-relations/home/investor_call_recording
· The disclosure was made in continuation of earlier filings dated May 20, 2026 and May 26, 2026
· Compliance under Regulation 30(6) of SEBI LODR

Fine Organic Industries Limited Regulatory Action mixed materiality 8/10

26-05-2026

Fine Organic Industries reported a modest 4.3% YoY revenue growth to INR 2,365 crore and a 1.6% YoY PAT increase to INR 417 crore for FY26, with EBITDA margin at 20.4%. The company announced the acquisition of an 80% stake in Oleofine Organics BHD (Malaysia) for approximately INR 82.9 crore, and provided updates on its JNPA (SEZ) project, a new US manufacturing subsidiary in South Carolina, and a Dubai subsidiary. However, the company faced elevated raw material costs, freight disruptions from the West Asia conflict, and uneven global demand, with management expecting raw material prices to remain high in the near term.

· All manufacturing facilities operated at near full capacity during FY26.
· Patalganga food additives facility is expected to reach full capacity in the next financial year.
· The OFM acquisition (80% stake) is expected to close within 3 months, subject to approvals.
· The JNPA (SEZ) project is expected to commence commercial production in FY28.
· Raw material prices increased marginally in Q4 FY26 vs Q3 FY26, and freight costs rose in Q4 due to West Asia conflict disruptions.
· Management expects palm oil and other vegetable oil prices to continue rising due to biodiesel mandates in Indonesia and Malaysia.
· The company is taking short-term orders (1-2 months) to manage raw material volatility.
· Customers have accepted FOB terms, absorbing freight risk for Middle East shipments.
· The US subsidiary has acquired 160 acres of land in South Carolina; contractor discussions are in advanced stage.
· The first phase of the US plant will be conservatively sized to manage operational learning curve.

Gandhar Oil Refinery (India) Limited Regulatory Action neutral materiality 7/10

26-05-2026

Gandhar Oil Refinery (India) Limited's Board of Directors approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion. The Board also approved the re-appointment of Joint Managing Directors Samir Parekh and Aslesh Parekh for another 5 years, the appointment of Santokhsingh Karamsingh Sandhu as an Additional Non-Executive Independent Director and Jatin Dhamani as Additional Whole Time Director, and the re-appointment of internal and cost auditors. Additionally, the Board approved the proposed incorporation of a wholly-owned subsidiary in South Africa and an agreement to purchase land in Raigad district.

· Audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026 received an unmodified (clean) audit opinion from KJK & Associates.
· Board re-appointed M/s. G. D. Singhvi & Co. as Internal Auditor and M/s. Maulin Shah & Associates as Cost Auditor for FY 2026-27.
· Board approved purchase of land at Village Kherane Khurd, Tal. Panvel, Dist. Raigad with plot size of approximately 21,551 sq. mtrs.
· Board approved proposed incorporation of a wholly-owned subsidiary in South Africa.
· Audit Committee reconstituted: Ms. Amrita Nautiyal as Chairperson, Mr. Ramesh Parekh and Mr. Raj Kishore Singh as members, with new member Mr. Santokhsingh Karamsingh Sandhu.
· Nomination and Remuneration Committee reconstituted: Mr. Raj Kishore Singh as Chairperson, Ms. Amrita Nautiyal and Mr. Santokhsingh Karamsingh Sandhu as members.
· Board meeting commenced at 3:00 p.m. and concluded at 6:30 p.m.